S DravidaTranscell Oncologics, India
Title: New Approach for Haploidentical Hematopoietic Stem Cell Transplantation Procedures – Transcell developed HEMATO in and as Technology Imperative Option for curing Cancers
HEMATO’s (www.HEMATO.global) Pregen is way ahead of just machine acquired genomics data, with its advanced bioinformatics engine fortified with proprietary AI tool. It looks into the genes isolated from DNA/RNA harvested from primary stem cells collected from the donor’s peripheral blood (5 ml). This test analyses genetic predispositions to various kinds of cancers and acts as a tool to publish health signature in selecting the donor in the family with cancer/s disease history or patients. Pregen personifies the donor for haploidentical Hematopoietic Stem Cell Transplantation (HSCT) procedures by enrolling the donor for Hemato Cryo that cryopreserves the healthy Hematopoietic Stem Cells (HSCs) with an option to enrich or deplete clinical grade single cell type fractions. MESEN is a prophylactic cell-based tool to address Graft Versus Host Disease from the same platform representing cell therapy model in imparting well equipped HSCT procedures to cure cancers
S Dravida PhD is a trained stem cell biologist with clinical informatics background. She is the founder and CEO of Transcell Oncologics with core program on drugging the undruggable. HEMATO is their dedicated vertical personalizing Hematopoietic Stem Cell Transplantation procedures based on cell therapy model with many firsts to it’s operating dogma. She is an inventor and has >25 patents and Intellectual property to her credit in this domain.